TY - JOUR
T1 - Mediterranean diet and antihypertensive drug use
T2 - A randomized controlled trial
AU - Ribó-Coll, Margarita
AU - Lassale, Camille
AU - Sacanella, Emilio
AU - Ros, Emilio
AU - Toledo, Estefanía
AU - Sorlí, José V.
AU - Babio, Nancy
AU - Lapetra, José
AU - Gómez-Gracia, Enrique
AU - Alonso-Gómez, Ángel M.
AU - Fiol, Miquel
AU - Serra-Majem, Lluis
AU - Pinto, Xavier
AU - Castañer, Olga
AU - Díez-Espino, Javier
AU - González, José I.
AU - Becerra-Tomás, Nerea
AU - Cofán, Montserrat
AU - Díaz-López, Andrés
AU - Estruch, Ramón
AU - Hernáez, Álvaro
N1 - Funding Information:
Sources of funding: This work was supported by: the Official College of Pharmacists of Barcelona (Col·legi Oficial de Farmacèutics de Barcelona, COFB), Instituto de Salud Carlos III (grant numbers: CB06/03/0019, CB06/03/0028, CD17/00122), and Agència de Gestió d’Ajuts Universitaris i de Recerca (grant numbers: 2017 SGR 222, 2017 BP 00021). CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of Instituto de Salud Carlos III, Madrid, Spain, and financed by the European Regional Development Fund. The sponsors of this study are public/nonprofit organizations that support science in general and had no role in gathering, analyzing, or interpreting the data.
Funding Information:
E.R. reports personal fees, grants, and nonfinancial support from the California Walnut Commission and Alexion; personal fees and nonfinancial support from Danone; and nonfinancial support from the International Nut Council. L.S.-M. reports being a board member of the Mediterranean Diet Foundation and the Beer and Health Foundation. X.P. reports being a board member, lecture fees, and grants from Ferrer International; being a board member and grants from the Residual Risk Reduction Initiative Foundation; personal fees from Abbott Laboratories; lecture fees and grants from Merck and Roche; lecture fees from Danone, Esteve, Menarini, Mylan, LACER, and Rubio Laboratories; and grants from Sanofi, Kowa, Unilever, Boehringer Ingelheim, and Karo Bio. R.E. reports being a board member of the Research Foundation on Wine and Nutrition, the Beer and Health Foundation, and the European Foundation for Alcohol Research; personal fees from KAO Corporation; lecture fees from Instituto Cerventes, Fundacion Dieta Mediterranea, Cerveceros de España, Lilly Laboratories, AstraZeneca, and Sanofi; and grants from Novartis, Amgen, Bicentury, and Grand Fountaine. The rest of the authors have nothing to disclose.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Objective:To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk.Methods:In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events.Results:Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74-0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60-0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003).Conclusion:In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users.
AB - Objective:To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk.Methods:In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events.Results:Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74-0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60-0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003).Conclusion:In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users.
KW - Mediterranean diet
KW - antihypertensive agent
KW - nutritional sciences
KW - preventive medicine
KW - randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85106539141&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000002765
DO - 10.1097/HJH.0000000000002765
M3 - Article
C2 - 33496530
AN - SCOPUS:85106539141
SN - 0263-6352
VL - 39
SP - 1230
EP - 1237
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 6
ER -